Abstract

Objective: AngioJet rheolytic thrombectomy (ART) has been used as a catheter-based treatment for acute pulmonary embolism (PE). In this study, based on our 7-year experience with ART in patients with PE, we evaluated the efficacy and safety outcomes of ART.

Methods: Our study is based on retrospective evaluation of 56 patients with high- and intermediate-high-risk PE, with an average age of 62 years (interquartile range [IQR] 50–73 years) who underwent ART.

Results: High and intermediate-high risks were noted in 21.4% and 78.6% of the patients, respectively. The ART duration was 304 (IQR: 246–468) seconds. Measures of obstruction, right to left ventricle diameter ratio, right to left atrial diameter ratio, and pulmonary arterial pressures were improved (p<0.001 for all). During the hospital stay, acute renal failure, major and minor bleeding, and mortality rates were 37.5%, 7.1%, 12.5%, and 8.9%, respectively. Aging related to post-procedural nephropathy while high-risk status was associated with in-hospital mortality (p=0.006) and long-term mortality.

Conclusion: ART resulted in significant and clinically relevant improvements in the pulmonary arterial thrombotic burden, right ventricle strain, and hemodynamics in patients with PE at high and intermediate-high risk. Aging increased the risk of post-procedural nephropathy, whereas baseline high-risk status predicted in-hospital and long-term mortality.

Keywords: pulmonary embolism, thrombectomy, mechanical thrombolysis, angioJet rheolytic thrombectomy

Introduction

Acute pulmonary embolism (PE) has been documented as the third most frequent lethal cardiovascular disease in the Western World (1, 2). Acute-onset hemodynamic instability owing to 30% to 50% thrombotic obliteration of the pulmonary arterial (PA) vessels and right ventricle (RV) strain manifested by RV diameter to left ventricle diameter ratio (RV/LVr) either assessed by echocardiography (Echo) or computed tomography (CT) has been documented to predict clinical worsening even in the low-risk status (1-3). The European Society of Cardiology/European Respiratory Society (ESC/ERS) 2014 and 2019 PE guidelines have recommended an updated acute phase treatment strategy based on the definition of high, intermediate-high, intermediate-low, and low-risk groups (1, 2). Patients at high-risk (HR) status have been considered to require urgent primary pharmacological (or alternatively, surgical, or interventional) reperfusion therapies (1, 2). Moreover, for patients who develop hemodynamic instability, rescue thrombolytic treatment (TT) has also been recommended; and catheter directed treatments (CDT) as an alternative to rescue TT should be considered (2). However, systemic TT has been documented to improve RV...
HIGHLIGHTS

• Although AngioJet rheolytic thrombectomy (ART) has been a black box warning as a treatment method for acute pulmonary embolism (PE), optimal duration and efficacy remain to be determined.
• This largest single-center study on ART performed in patients with PE at intermediate-high and high risk has resulted in significant improvements in obstructive burden and hemodynamics. High-risk status is related to early and long-term mortality.
• ART may be considered in patients with PE and with multiple comorbidities and a tendency to bleed.

Dysfunction and hemodynamic status at the expense of the increased risk of major bleeding events, including intracranial hemorrhage (1-5).

Among the several CDT systems, only three devices have been approved by the Food and Drug Administration (FDA) (6-9). Experience with other CDT systems in sub-massive or massive PE has been based on off-label utilization in anecdotal case reports, small retrospective series comprising highly selected patient groups, and systematic reviews or meta-analyses of heterogeneous datasets (10-13). Only one of these, an ultrasound-assisted thrombolysis technology, EkoSonic® Endovascular System (Boston Scientific Corporation, USA), was tested in randomized clinical trials (7, 8, 14) and has been reported to facilitate thrombolysis with reduced lytic dosages, which leads to lowered bleeding risk in patients with PE at high and intermediate-high-risk (IHR) status (7, 8, 14-17).

The AngioJet rheolytic thrombectomy (ART) (Possis Medical, Minneapolis, Minnesota, USA) system is a widely used CDT device that uses high pressure and circumferential saline jet expulsions at the catheter tip (2,500 psi or 1.7–10⁷ Pa) to create a local low-pressure zone via Bernoulli’s principle of fluid dynamics to entrain, fragment, and aspirate thrombi even if the catheter is positioned several millimeters away from the occlusive clot. Moreover, the on-the-wire design of ART permits aspiration thrombectomy procedures along all the subsegmentary pulmonary artery branches selected (18-25). ART seems to be an efficacious CDT device in terms of thrombus fragmentation/aspiration, as well as improvement of clinical measures in massive and sub-massive PE (18-25). However, the mortality rate in unstable settings remains high, and a controversy exists regarding the safety of ART (18-28).

In this study, we aimed to evaluate our 7-year experience with ART in patients with PE at HR or IHR and to assess predictors of efficacy and safety outcomes following this CDT.

Methods

Our study population included 56 patients [average age 62 years, interquartile range (IQR) 50–73 years, 24 (46.9%) women of 710 patients] referred to our tertiary cardiovascular center with a diagnosis of acute PE and who underwent ART treatment with various indications from October 2012 to November 2020. The patients were evaluated retrospectively. The systematic work-up for an initial diagnosis of acute PE, and risk stratification comprising the multidetector contrast-enhanced CT angiography and Echo assessments, PE severity indexes, and biomarker evaluation have been based on the criteria recommended by the ESC/ERS 2014 and 2019 PE guidelines (1, 2).

Inclusion criteria were acute symptomatic PE confirmed by CT pulmonary angiography and Echo assessments, PE severity indexes, and biomarker evaluation have been based on the criteria recommended by the ESC/ERS 2014 and 2019 PE guidelines (1, 2).

In this study, we aimed to evaluate our 7-year experience with ART in patients with PE at HR or IHR and to assess predictors of efficacy and safety outcomes following this CDT.

Right heart catheterization, pulmonary angiography, and ART procedure

Only the femoral venous route with a 6-French (F) sheath was used, and arterial puncture was avoided. A 6F multipurpose catheter was used for initial PA pressure measurements and selective angiograms. The selective placements of the multipurpose catheter were followed by exchange with a 6F sheathless catheter over a 0.35-inch hydrophilic guidewire. The ART catheter was connected to the aspiration system and advanced to the proximity of the occluded pulmonary artery over the guide wire. The fragmentation/aspiration sequences were activated for 15 to 20 seconds with manual antegrade advancements throughout the thrombotic obstruction under fluoroscopic guidance and were repeated until satisfactory reperfusion was achieved. In cases of patients in whom sinus bradycardia and/or atrioventricular conduction disturbances occurred immediately at the moment of system activation, ART was deactivated for 30 to 60 seconds until the recovery of normal sinus rhythm.

Local intrapulmonary infusion of adjuvant recombinant tissue-type plasminogen activator (t-PA) was also used in cases of patients with massive thrombotic occlusions threatening the perfusion of large pulmonary territories. Intravenous heparin was started after termination of the ART procedure, and the aim was to keep the activated partial thromboplastin time around 60 seconds. In cases of patients with acute-onset heparin-induced thrombocidemia, fondaparinux or rivaroxaban...
were preferred. In accordance with currently available PE practice guidelines, a minimum of 6 months of anticoagulant therapy with warfarin, rivaroxaban, apixaban, or edoxaban was recommended.

**Chest CT pulmonary angiography**

Images were acquired before and 3 to 4 days after the ART procedure using a 64-slice helical CT scanner (Toshiba Aquilion 64™, Toshiba Medical Systems Corp., Tokyo, Japan) with angiographic contrast material (Omnipaque 350), and the stored images were evaluated. A validated CT score for pulmonary arterial occlusion proposed by Qanadli et al. (29) [Qanadli score (QS)], RV/LVr, right atrial to left atrial diameter ratio (RA/LAr), and main, left, and right pulmonary arterial diameters were measured from CT images as reported previously (15-17).

**Efficacy measures**

Improvements in the measures of pressure overload and RV function, including RV/LVr, RA/LAr, QS, and pulmonary arterial diameters quantitated by CT; longitudinal RV function measures including tricuspid annular plenary systolic excursion (TAPSE); tissue velocity assessed by echocardiography; and pulmonary arterial systolic and mean pressure estimates were used as surrogates for acute efficacy of ART compared with baseline.

**Safety measures**

Safety outcomes included minor and non-fatal major bleeding and all-cause mortality during the in-hospital period following ART. Long-term follow-up data were also included in the analysis for mortality and bleeding outcomes. Major bleeding was defined as overt bleeding associated with a fall in the hemoglobin level of at least 2.0 g/dL or with the transfusion of 2 units of packed red blood cells or involvement of a critical site. A clinically overt bleeding not fulfilling the criteria for a major bleeding was classified as a minor bleeding (30). The post-procedural nephropathy (PPN) was evaluated in patients using the criterion of an increase of 0.5 mg/dL in plasma creatinine levels or a 25% increase in basal creatinine within 72 hours after the procedure recommended by the European urogenital radiology community (31). Because of its retrospective nature, informed consent was not required to participate in the study.

**Statistical analysis**

The Shapiro-Wilk test was used to determine whether the distribution of variables was normal. We preferred to use median ± IQR for continuous variables. Non-normally distributed continuous variables were presented as median and IQR (quartile 1 to quartile 3). Normally distributed variables were presented as mean ± standard deviation. The Mann-Whitney U test was used to compare the two independent groups. Categorical variables were presented as counts and percentages. Categorical variables were compared using the chi-squared test and Fisher exact test as appropriate. In addition, echocardiographic, CT, and vital measures before and after ART were compared for all the patients using the Wilcoxon test. The survival curves were constructed using the Kaplan-Meier method, and groups were compared using the log-rank test.

Dependent variables were the RV/LV ratio, QS, and pulmonary artery systolic pressure (PASP) change.

**Post-procedural nephropathy**

As a rule of thumb, there should be at least 10 patients with an outcome in relation to the degrees of freedom of the predictors included in the model (outcome/degrees of freedom = n-10). In our PPN model, 4 predictors were identified, whereas outcomes (PPN) were present in 21 patients (21/4=5.25). Therefore, multivariate logistic regression analysis was used to evaluate the association between CIN and 4 candidate predictors of overfitting risk. Our regression model includes predictor variables such as age, contrast volume, QS, and baseline creatinine. All statistical analyses were performed using “rms,” “Hmisc,” “survminer,” “survival,” and “ggplot2” packages with R version 4.01 (R Project, Vienna, Austria).

**Results**

A total of 56 patients with PE with IHR or HR status were treated with ART. Patient characteristics, comorbidities, and treatment patterns are presented in Table 1. Baseline risk statuses were IHR or HR in 78.6% and 21.4% of the patients, respectively. The median time delays from symptoms to ART treatment and from ART to post-procedural CT acquisition were 3.5 (2–5.25) and 5 (4–6) days, respectively. Moreover, ART was performed after the failure of systemic t-PA or ultrasound-assisted thrombolysis in 5 patients, and CT measures obtained after termination of t-PA infusion were used as baseline reference for assessing the efficacy of ART in these cases. Absolute or relative contraindications for t-PA, including active bleeding from esophageal varices, recent or active major bleeding, in-hospital PE immediately after major surgery, and intracranial metastasis or bleeding were noted in 10 (83.3%) patients at HR and in 20 (45.4%) patients at IHR (Table 1).

The system catheters were successfully placed in all the patients. Unilateral and bilateral ART treatments were needed in 22 (39.3%), and 34 (60.7%) patients, respectively. Bilateral ART treatments were needed in 33.3% of the patients at high-risk and 68.2% of the patients at intermediate-high risk. Overall, the ART activation duration was 304 (246–468) seconds. Adjuvant t-PA was used in 19 (33.9%) patients, and the lytic dosage was 15 mg (10–20). The tPA was given intravenously to 9 patients; the activated t-PA was used in 19 (33.9%) patients, and the lytic dosage was 15 mg (10–20). The tPA was given intravenously to 9 patients; the median intravenous dose was 27.5 mg for both groups, and the median infusion duration was 6 hours for IHR and 2 hours for HR patients. Mechanical ventilation and extracorporeal membrane oxygenation (ECMO) were needed in 5 and 2 patients, respectively (Table 1). Treatment characteristics were comparable between patients at HR and IHR. All the clinical, echo, and CT measures of RV systolic strain and dysfunction, QS, and PA pressure estimates were significantly improved after ART (Fig. 1, Table 2). Comparison of improvements in these measures...
| Variables                                      | All          | IHR (n=44)  | HR (n=12)  | P-value |
|-----------------------------------------------|--------------|-------------|------------|---------|
| Age (years)                                   | 62 (50–73)   | 66 (50.8–73.3) | 56 (36.3–62) | 0.097   |
| Male sex, n (%)                               | 32 (57.1%)   | 22 (50%)    | 10 (83.3%) | 0.039   |
| Diabetes mellitus, n (%)                      | 15 (26.8%)   | 12 (27.3%)  | 3 (25%)   | 0.875   |
| Hypertension, n (%)                           | 24 (42.9%)   | 21 (47.7%)  | 3 (25%)   | 0.158   |
| Atrial fibrillation, n (%)                    | 3 (5.4%)     | 36.8%       | –         | 0.999   |
| Syncope                                       | 25 (44.6%)   | 17 (38.6%)  | 8 (66.7%) | 0.083   |
| Chronic obstructive lung disease, n (%)       | 5 (8.9%)     | 4 (9.1%)    | 1 (8.3%)  | 0.999   |
| Previous coronary artery disease, n (%)       | 11 (19.6%)   | 8 (18.2%)   | 3 (25%)   | 0.598   |
| Previous pulmonary embolism, n (%)           | 7 (12.5%)    | 5 (11.4%)   | 2 (16.7%) | 0.622   |
| Presence of deep vein thrombosis, n (%)       | 37 (66.1%)   | 29 (65.9%)  | 8 (66.7%) | 0.999   |
| Possible secondary causes, n (%)              |              |             |           |         |
| Malignancy                                    | 15 (26.8%)   | 12 (27.3%)  | 3 (25%)   | 0.999   |
| Orthopedic surgery/fractures                  | 7 (12.5%)    | 8 (13.6%)   | 1 (8.3%)  | 0.999   |
| Previous stroke history                       | 6 (10.7%)    | 4 (9.1%)    | 2 (16.7%) | 0.599   |
| Prolong traveling                             | 3 (5.4%)     | 3 (6.8%)    | –         | 0.999   |
| Postoperative status                          | 17 (30.4%)   | 10 (22.7%)  | 7 (58.3%) | 0.043   |
| Thrombophilia                                 | 2 (3.6%)     | 2 (4.5%)    | –         | 0.999   |
| Immobility                                    | 3 (55.4%)    | 22(50%)     | 9 (75%)   | 0.191   |
| Pulmonary infarction, n (%)                   | 5 (16.7%)    | 2 (9.1%)    | 3 (37.5%) | 0.102   |
| Pleural effusion, n (%)                       | 6 (20%)      | 3 (13.6%)   | 3 (37.5%) | 0.300   |
| Baseline vital signs                          |              |             |           |         |
| Heart rate/min                                | 112 (103–125)| 110 (100–120)| 132 (122–143)| <0.001 |
| Systolic blood pressure, mm Hg                | 127 (104–136)| 132 (119–136)| 90.5(88–92.8)| <0.001 |
| Diastolic blood pressure, mm Hg               | 71 (60–81)   | 79 (69.3–83.3)| 56.5 (50–60)| <0.001 |
| Oxygen saturation, %                          | 88 (84.8–91.3)| 88.5 (85–92) | 85.5 (79–87.5)| 0.032 |
| Baseline laboratory variables                 |              |             |           |         |
| Troponin, ng/mL                               | 0.12 (0.06–0.36)| 0.1 (0.06–0.25)| 0.23 (0.09–0.59)| 0.209 |
| D–Dimer, U/mL                                 | 7 (3.4–14.4) | 5.03 (2.98–11.7) | 17.9 (9.35–20) | 0.011 |
| C–reactive protein                            | 3.78 (2.0–10.4)| 3.46 (1.93–7.47)| 12.3 (4.84–18.7)| 0.034 |
| Symptom duration (days)                       | 5 (2.0–5.25) | 4 (2.0–5.25) | 2.5 (1.75–5.50) | 0.413 |
| PESI                                          | 117 (97.8–129)| 106 (88.3–125)| 135 (120–151)| 0.003 |
| PESI Class                                    | 4 (3–5)      | 4 (3–4.25)  | 5 (4–5)   | 0.002   |
| Simplified PESI                               | 2 (1–2.25)   | 2 (1–2)     | 3 (2.75–3) | <0.001 |
| Absolute or relative contraindications to thrombolytic | 30 (53.6%) | 20 (45.4%) | 10 (83.3%) | 0.001 |
| Intracranial bleeding                         | 4 (7.1%)     | 2 (4.5%)    | 2 (16.7%) | 0.191   |
| Active bleeding                               | 3 (5.36%)    | 2 (4.5%)    | 1 (8.3%)  | 0.515   |
| Recent major bleeding                         | 3 (5.36%)    | 3 (6.8%)    | –         | 0.999   |
| Recent major surgery                          | 9 (16%)      | 9 (20.4%)   | 5 (41.7%) | 0.134   |
| Recent head trauma                            | 4 (7.14%)    | 3 (6.8%)    | 1 (8.3%)  | 0.999   |
| Intracranial metastasis                       | 1 (1.78%)    | 1 (2.27%)   | 1 (8.3)   | 0.999   |

**ART** - AngioJet rheolytic thrombectomy, **HR** - high-risk, **IHR** - intermediate-high risk, **PESI** - pulmonary embolism severity indices
Table 2. Echocardiographic, CT, and vital measures before and after ART

| Variables                          | Before ART | After ART | Mean change | P-value |
|------------------------------------|------------|-----------|-------------|---------|
| PASP (mm Hg)                       | 56.7±14.3  | 40.2±13.4 | 16.4        | <0.001  |
| RV/LV ratio                        | 1.33±0.24  | 0.92±0.18 | 0.41        | <0.001  |
| RA/LA ratio                        | 1.39±0.40  | 0.95±0.17 | 0.44        | <0.001  |
| TAPSE (cm)                         | 1.75±0.34  | 2.17±0.36 | -0.42       | <0.001  |
| ST (cm/sec)                        | 10.68±2.22 | 13.46±1.99| -2.77       | <0.001  |
| QS                                 | 24.2±6.23  | 11.92±6.89| 12.27       | <0.001  |
| Main PA diameter (mm)              | 28.16±8.17 | 27.75±4.51| 0.41        | <0.001  |
| Heart rate (bpm)                   | 110.5±17.1 | 84.2±11.5 | 26.1        | <0.001  |
| Systolic blood pressure (mm Hg)    | 123.3±21.1 | 123.2±14.4| 0.1         | 0.865   |
| Oxygen saturation (%)              | 87.7±5.3   | 94.5±2.5  | -6.8        | <0.001  |
| Shock index                        | 0.93±0.27  | 0.69±0.13 | 0.23        | <0.001  |
| Modified shock index               | 0.01±0.003 | 0.007±0.001| 0.003       | <0.001  |

ART - AngioJet rheolytic thrombectomy, PA - pulmonary artery, PASP - pulmonary arterial systolic pressure, RV - right ventricle, LV - left ventricle, RV/LV - right ventricle to left ventricle diameter ratio, RA/LA - right atrial to left atrial diameter ratio, TAPSE - tricuspid annular planary systolic excursion, ST - tricuspid annular systolic velocity on tissue Doppler, QS - Qanadli score

Table 3. Comparisons of age and risk groups for percent and absolute changes in the measures of efficacy

| Change in measures | <65 years | >65 years | P-value | IHR | HR | P-value |
|--------------------|-----------|-----------|---------|-----|----|---------|
| RV/LV diameter ratio (%) | 30.9 (0.20–0.42) | 26.7 (21.3–32) | 0.255 | 30.5 (21.4–40.9) | 24.4 (15.9–30.4) | 0.163 |
| RV/LV diameter ratio (absolute) | 0.41 (0.24–0.61) | 0.33 (0.25–0.42) | 0.173 | 0.73 (0.26–0.55) | 0.30 (0.17–0.44) | 0.273 |
| PASP (%)           | 33.3 (17.5–45.0) | 30.0 (17.4–42.7) | 0.895 | 30 (16.7–40.0) | 45.0 (19.4–47.3) | 0.173 |
| PASP (absolute, mm Hg) | 15 (7–25) | 17 (11–28.5) | 0.335 | 15.0 (10.2–22.8) | 26 (10.0–29.0) | 0.213 |
| QS (%)             | 59.3 (38.7–75) | 53.6 (26.7–62.5) | 0.234 | 50.8 (31.8–68.2) | 61.3 (57.1–70.5) | 0.194 |
| QS (absolute)      | 14 (9–18) | 11 (5–15.8) | 0.112 | 11 (7.5–15.5) | 18.5 (11.8–21.5) | 0.015 |

IHR - intermediate-high risk, HR - high risk, PASP - pulmonary arterial systolic pressure, RV - right ventricle, LV - left ventricle, RV/LV - right ventricle to left ventricle diameter ratio, RA/LA - right atrial to left atrial diameter ratio, TAPSE - tricuspid annular planary systolic excursion, ST - tricuspid annular systolic velocity on tissue Doppler, QS - Qanadli score

between HR versus IHR subgroups, and older versus younger age groups according to the cut-off limit of 65 years is given in Table 3.

Transient bradyarrhythmia’s spontaneously terminating immediately after deactivation of ART were noted in 18 (32.1%) of patients and were comparable between risk groups (Table 4). Gross hemoglobinuria following ART was uniformly observed. However, hemoglobinuria recovered within 24 hours in all the patients with saline over hydration. Transient renal failure was noted in 22 (39.3%) patients regardless of the risk groups (Table 4). Penalized logistic regression revealed that age was the only independent predictor of post-procedural nephropathy [age 50–73, odds ratio (OR) 2.12 (1.05–4.24), 95% confidence interval (CI) 1.05–4.24, p=0.034] (Table 5).

During a hospital stay of a median of 13 (IQR 9–17) days, 5 (8.9%) patients died; and intracranial and unresolved severe PE were associated with mortality in 1 (1.8%) and 4 (7.1%) patients, respectively (Table 4). ECMO was needed in 2 of the 4 of these mortal cases. Non-fatal major bleeding was documented in 4 (7.1%) patients and included intracranial, hemoptysis, and gastrointestinal bleeding in 1, 1, and 2 episodes, respectively. Minor bleeding events were noted in 7 (12.5%) patients; and groin hematoma, hemoptysis, hematuria, hemorrhoidal, and menstrual bleeding were observed in 1, 3, 1, 1, and 1 episode, respectively. HR versus IHR statuses were associated with higher in-hospital mortality (33.3% versus 2.3%, p=0.006), whereas major or minor bleeding rates were comparable (p=0.999 and p=0.325, respectively) (Table 4).

The 3 criteria were defined for assessment of clinical efficacy as follows; systolic blood pressure ≥110 mm Hg, pulse O2 saturation >90% at discharge, and absence of in-hospital mortality and major bleeding; systolic blood pressure ≥100 mm Hg, O2 saturation >90% at discharge, and absence of in-hospital mortality and major bleeding; and only O2 saturation >90 at discharge. According to these definitions, the efficacy rates were 66.1%, 71.5%, and 84%, respectively.

Heparin-induced thrombocytopenia occurred in 2 patients, and fondaparinux was used in these patients. Post-discharge follow-up data based on periodic clinical and telephone controls for a median of 1,258 (425–1,698 days) was available for all the patients. The Kaplan-Meier survival curves and log-rank tests revealed that long-term event-free survival probability seemed to be associated with IHR status, but not with aging (Fig. 2 and 3).
Discussion

This study, based on our 7-year experience with ART in patients with acute PE at HR and IHR, represents the largest single-center data for this percutaneous PE treatment system. Although ART was associated with significant improvements in pulmonary arterial obstruction, right heart strain, and hemodynamics, bleeding and mortality risks were not negligible. Fatal bleeding and unresolved PE accounted for 20% and 80% of in-hospital deaths, respectively. Aging related to transient nephropathy after ART with HR status predicted higher in-hospital mortality and long-term mortality.

The idea of risk-adjusted PE treatment strategies providing the benefits of efficacy outcomes with a low bleeding risk has remained an unmet need for at least four decades (1-13). The vast majority of data regarding the efficacy and safety concerns of CDTs has been derived from registries and pooled analyses of case series, which could suffer from publication bias. None of these provided robust evidence (based on conflicting results of efficacy and safety issues of CDTs, except two currently available CDT systems having FDA approval) (10-13) for the superiority of one CDT over others in sub-massive or massive PE (7-9). A meta-analysis of earlier CDT studies showed an 86.5% overall clinical success rate with 7.9% and 2.4% pooled rates of minor and major procedural complications, respectively (10).

The most frequently reported complications of ART are transient bradycardia’s and asystole, which are considered to be secondary to hemolysis followed by adenosine release occurring at activation bursts (27, 28). However, short bursts (usually less than 10 pulses at a time) with intervals of 20–30 seconds between activations usually allow for clearance of compounds such as adenosine and recovery of normal sinus rhythm (27, 28). Another controversial issue, the potential for local thermal injury related to ART, was investigated in human saphenous vein segments mounted in an ex vivo perfusion system (26). Continuous ART for 4 minutes and pulsed ART for eight cycles of 30 seconds, followed by 10 seconds of deactivation, were reported to produce a mean 7.61°C and 7.31°C increase in temperature above baseline, with mean maximum temperatures of 44.11°C and 43.81°C, respectively (26). In comparison to those in untreated segments, ART resulted in a significant intima/media thinning with a reduction in intact endothelium and an increase in staining for heat shock protein 90 expression with immunohistology staining (26). These results seem to be consistent with a potential risk for local thermal injury with or without

Table 4. Characteristics of ART, adjuvant thrombolytic regimen, and complications in HR and IHR groups

| Measures                                    | Total (n=46) | IHR (n=44) | HR (n=12) | P-value |
|---------------------------------------------|-------------|------------|-----------|---------|
| Treatment regimens                          |             |            |           |         |
| Bilateral ART, n (%)                        | 34 (60.7%)  | 30 (68.2%) | 4 (33.3%) | 0.044   |
| ART activation duration (seconds)           | 304 (246–468)| 300 (246–443)| 348 (274–480)| 0.663 |
| Need for adjuvant t-PA via catheter (%)     | 19 (33.9)   | 16 (36.3%) | 3 (25%)   | 0.732   |
| Intraprocedural total t-PA dose             | 15 (10–20)  | 14 (10–20) | 20 (15–21.3)| 0.245  |
| IV t-PA dose                                | 27.5 (18.8–63.8)| 25 (0–50) | 60 (42.5–80) | 0.301   |
| ECMO need                                   | 2 (3.6%)    | 0          | 2 (8.3%)  | 0.999   |
| Transient bradycardia and/or atrioventricular block | 18 (32%)  | 13 (29.5%) | 5 (41.7%) | 0.494   |
| Peri-procedural nephropathy                 | 22 (39.3%)  | 20 (45.5%) | 2 (16.7%) | 0.101   |
| Transient hemodialysis need                 | 1 (1.8%)    | 1 (2.2%)   | –         | 0.999   |
| Major bleeding                              | 4 (7.1%)    | 3 (6.8%)   | 1 (8.3%)  | 0.999   |
| Minor bleeding                              | 7 (12.5%)   | 7 (15.9%)  | –         | 0.325   |
| In-hospital mortality                       | 5 (8.4%)    | 1 (2.3%)   | 4 (33.3%) | 0.006   |
| Median hospital stay (days)                 | 13 (9–17)   | 14 (10–19) | 8 (3.5–13.5)| 0.012  |

ART - AngioJet rheolytic thrombectomy, IHR - intermediate-high risk, HR - high risk, t-PA - tissue-type plasminogen activator, ECMO - extracorporeal membrane oxygenation

Table 5. Penalized multivariable logistic regression for prediction post-procedural nephropathy

| Variables                                      | OR (95% CI)     | P-value |
|------------------------------------------------|-----------------|---------|
| Baseline creatinine (from 0.65 to 0.96), mg/dL | 0.64 (0.33–1.21)| 0.177   |
| QS (20 to 28)                                  | 0.89 (0.45–1.75)| 0.744   |
| Age (50 to 73), years                          | 2.12 (1.05–4.24)| 0.034   |
| Contrast volume (98 to 184), mL                | 1.04 (0.50–2.22)| 0.912   |

ART - AngioJet rheolytic thrombectomy, CI - confidence interval, OR - odds ratio, QS - Qanadli score
Figure 1. Individual changes in pulmonary arterial systolic pressure, Qanadli score, and right ventricle to left ventricle diameter ratio

Figure 2. Comparison of patients at high-risk versus intermediate-high-risk status by Kaplan-Meier survival estimates
mechanical damage in the treated vessel segments, especially in cases of longer activation durations (26).

Additional concerns related to hemolysis are the occurrence of severe hyperkalemia and hemoglobinuria (22-25, 28). Hyperkalemia may exacerbate the electrical instability, and hemoglobinuria may cause acute deterioration of kidney function in these patients already at risk because of hemodynamic instability and contrast utilization for diagnostic computed tomography angiographic evaluation and selective pulmonary arterial injections during the ART procedure (22-25, 28).

In an early meta-analysis of 68 patients treated with ART, the rates of major and minor complications and procedure-related deaths were 28% and 40%, and 7.35%, respectively (10). More importantly, 76% of all major complications were reported to be attributable to ART, and the authors concluded that this device should not be used as the initial mechanical treatment in future CDT protocols for patients with acute massive PE (10). Accordingly, the FDA has issued a black box warning on the commercially available ART device label pertaining to its use in patients with acute PE. In another meta-analysis of 14 studies that included a total of 197 patients with PE, rates of technical and/or clinical success in massive and sub-massive PE groups were 86.8% and 94.3% and in-hospital mortality was 23.7% and 13.2%, respectively. A total of 22 device-related major and minor complications were observed in 15.7% of the patients.

A recently published single-center ART study, which included 44 patients with acute PE in total (21 HR and 23 IHR), provided robust data for efficacy and safety concerns of this CDT system (25). The mean duration of overall ART activation runs was 156.6±59.1 seconds (ranging from 78 to 280 seconds), and adjunctive local urokinase was used in 90.9% of them (25). ART resulted in significant improvement in clinical, hemodynamic, and angiographic parameters, including perfusion, obstruction, and total Miller indexes, and IHR versus HR PE was associated with more obvious improvements in shock index, pulse oximetric percent saturation, and angiographic parameters and a significantly shorter stay in the intensive care unit (25). The in-hospital mortality rate was 13.6% and was significantly associated with HR status or shock. Renal failure requiring hemodialysis was observed in 13.6% of the patients and more frequently in patients at HR (25). The Echo showed a significant decrease in the PA mean pressure with improvement or normalization in right ventricular function, and CT pulmonary angiography revealed that the majority of the central and lobar arteries were clot free at the sixth month post-procedural assessment (25). Compared with this study, the duration of ART activation was markedly longer (median 304 seconds), and either the percent adjuvant t-PA (33.9%) or the median lytic dose was 15 mg (10–20) were lower in our series, including multiple comorbidities. Although post-procedural nephropathy was observed in 39.3% of our patients after ART, one-session dialysis was required in only 1

![Figure 3. Comparison of age groups (<65 versus >65 years) by Kaplan-Meier survival estimates](image-url)
(1.8%) patient, and all the patients recovered with saline over hydration. Older age, but not risk status or duration of ART activation, was related to acute nephropathy.

In another ART series that included 32 patients with massive (71.9%) or submassive (28.1%) PE, technical success was reported to be 100%, and 96.9% of them survived till discharge (24). Improvements in RV strain and pulmonary arterial pressure were achieved in all the survivors within 48 hours of the ART. Post-discharge four-week echo and CT assessments showed normalization of RV strain and pulmonary pressure measures in all the patients and complete resolution of thrombus in 79.3% of patients (24).

Study limitations

The retrospective nature of the analysis and operator-driven decisions for the total duration of ART activation runs and adjuvant lytic regimen were the main limitations of this study. Comparison with a heparin alone arm in the IHR group and with a fixed dose intravenous t-PA alone arm in the HR group might provide more relevant data in terms of efficacy and safety outcomes of ART therapies. Moreover, compared with the currently approved ultrasound-assisted thrombolysis system concomitant with different t-PA regimes as tested in a randomized trial (14), efficacy and safety concerns of ART in a randomized fashion might provide valuable data for IHR and HR PE groups.

Conclusion

Our experience showed that ART was associated with clinically relevant improvements in the measures of pulmonary arterial obstruction, RV strain, and hemodynamics in patients with PE at HR and IHR. Aging increased the risk of renal failure, whereas baseline HR status predicted in-hospital and long-term mortality. These results seem to suggest the need for reappraisal of the use of ART in patients with PE.

Acknowledgment: All the statistical analyses were performed by Ibrahim Halil Tanboğa, MD, Professor of Cardiology and Assistant Professor of Biostatistics. All clinical presentations, CT findings, and treatment strategies were discussed with Mehmet Yanartaş, M.D. and Serpil Gezer, M.D., Professors of Cardiovascular Surgery, and Erdal Taşıçı, M.D., and Bedrettin Yıldızeli, M.D., Professors of Thoracic Surgery, and Betül Özdere Kurtuluş, M.D., Radiologist, Ayşe Nigar Halis, MD, Pınar Atağin Güney, Chest Physicians, and Tuncer Koçak, M.D. and Emre Gürçü, M.D., Anesthesiologists, members of institutional multidisciplinary ECMO team. With our cordial thanks to Mehtap Altıntaş for her invaluable and limitless technical assistance in all rheolytic thrombectomy procedures.

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Author contributions: Concept – Ö.Y.A., B.Keskin, H.C.T., A.H., A.K., C.K.; Design – Ö.Y.A., S.T., B.Kültürsay, Ş.K., Z.B., I.H.T., C.D., C.K.; Supervision – Ö.Y.A., B.Keskin, S.T., B.Kültürsay, Ş.K., Z.B., A.E., I.H.T., C.K.; Fundings – None; Materials – Ö.Y.A., Z.B., S.C.E., C.D., M.A., N.Ö.; Data collection &/or processing – Ö.Y.A., B.Keskin, H.C.T., A.K., S.T., B.Kültürsay, C.K.; Analysis &/or interpretation – Ö.Y.A., B.Keskin, A.H., A.K., A.E., I.H.T., C.D., N.Ö., C.K.; Literature search – Ö.Y.A., B.Keskin, A.K., S.T., B.Kültürsay, Ş.K., Z.B., I.H.T., M.A., N.Ö., C.K.; Writing – Ö.Y.A., B.Keskin, A.K., S.T., B.Kültürsay, Ş.K., Z.B., I.H.T., M.A., N.Ö., C.K.; Critical review – Ö.Y.A., B.Keskin, H.C.T., A.H., A.K., S.T., B.Kültürsay, Ş.K., Z.B., S.C.E., A.E., I.H.T., C.D., M.A., N.Ö., C.K.

References

1. Konstantinides SV, Torbicki A, Gagnelii G, Danchin N, Fitzmaurice D, Galiè N, et al.; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033-69. [Crossref]

2. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al.; The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54: 1901647. [Crossref]

3. Barco S, Mahmoudpour SH, Planquette B, Sanchez O, Konstantinides SV, Meyer G. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2019; 40: 902-10. [Crossref]

4. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 2014; 311: 2414-21. [Crossref]

5. Marti C, John G, Konstantinides S, Combscure C, Sanchez O, Lankel M, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2015; 36: 605-14. [Crossref]

6. Greenfield LJ, Bruce TA, Nichols NB. Transvenous pulmonary embolectomy by catheter device. Ann Surg 1971; 174: 881-6. [Crossref]

7. Kucher N, Boekstegers P, Müller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129: 479-86. [Crossref]

8. Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engellardt TC, Sterling KM, et al.; SEATTLE II Investigators. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. JACC Cardiovasc Interv 2015; 8: 1382-92. [Crossref]

9. Tu T, Toma C, Tapson VF, Adams C, Jaber WA, Silver M, et al.; FLARE Investigators. A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism: The FLARE Study. JACC Cardiovasc Interv 2019; 12: 859-69. [Crossref]

10. Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 2009; 20: 1431-40. [Crossref]
11. Kuo WT, Banerjee A, Kim PS, DeMarco FJ Jr, Levy JR, Facchini FR, et al. Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): Initial Results From a Prospective Multicenter Registry. Chest 2015; 148: 667-73. [Crossref]

12. Bajaj NS, Kalra R, Arora P, Ather S, Guichard JL, Lancaster WJ, et al. Catheter-directed treatment for acute pulmonary embolism: Systematic review and single-arm meta-analyses. Int J Cardiol 2016; 225: 128-39. [Crossref]

13. Giri J, Sista AK, Weinberg I, Kearon C, Kumbhani DJ, Desai ND, et al. Interventionsal Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. Circulation 2019; 140: e774-801. [Crossref]

14. Tapson VF, Piazza G, Goldhaber S, Sterling K, Ouriel K, Liu PY. OPPtimum Duration and Dose of r-tPA with the Acoustic Pulse ThrombolySis ProcEdure for Intermediate-Risk (Submassive) Pulmonary Embolism: OPTALYSE PE. Am J Respir Crit Care Med 2017; 195: A2835. [Crossref]

15. Kaymaz C, Öztürk S, Akbal Ö, Tanboğa IH, Yılmaz F, Poçi N, et al. Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: Results From a Single-Center Cohort. Angiology 2017; 68: 433-40. [Crossref]

16. Kaymaz C, Akbal OY, Tanboga IH, Hakgor A, Yilmaz F, Ozturk S, et al. Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: A Meta-Analysis. Curr Vasc Pharmacol 2018; 16: 179-89. [Crossref]

17. Kaymaz C, Akbal OY, Hakgor A, Tokgoz HC, Karagöz A, Tanboğa IH, et al. A five-year, single-centre experience on ultrasound-assisted, catheter-directed thrombolysis in patients with pulmonary embolism at high risk and intermediate to high risk. EuroIntervention 2018; 14: 1136-43. [Crossref]

18. Margheri M, Vittori G, Vecchio S, Chechi T, Falchetti E, Spaziani G, et al. Early and long-term clinical results of AngioJet rheolytic thrombectomy in patients with acute pulmonary embolism. Am J Cardiol 2008; 101: 252-8. [Crossref]

19. Chechi T, Vecchio S, Spaziani G, Giuliani G, Giannotti F, Arcangeli C, et al. Rheolytic thrombectomy in patients with massive and submassive acute pulmonary embolism. Catheter Cardiovasc Interv 2009; 73: 506-13. [Crossref]

20. Vecchio S, Vittori G, Chechi T, Spaziani G, Lilli A, Giuliani G, et al. Percutaneous rheolytic thrombectomy with AngioJet for pulmonary embolism: methods and results in the experience of a high-volume center. G Ital Cardiol (Rome) 2008; 9: 355-63. [Article in Italian]

21. Bonvini RF, Roffi M, Bounnameaux H, Noble S, Müller H, Keller PF, et al. AngioJet rheolytic thrombectomy in patients presenting with high-risk pulmonary embolism and cardiogenic shock: a feasibility pilot study. EuroIntervention 2013; 8: 1419-27. [Crossref]

22. Bunwaree S, Roffi M, Bonvini JM, Noble S, Righini M, Bonvini RF. AngioJet® rheolytic thrombectomy: a new treatment option in cases of massive pulmonary embolism. Interv Cardiol 2013; 5: 71-87. [Crossref]

23. Das S, Das N, Serota H, Vissa S. A retrospective review of patients with massive and submassive pulmonary embolism treated with AngioJet rheolytic thrombectomy with decreased complications due to changes in thrombolytic use and procedural modifications. Vascular 2018; 26: 163-8. [Crossref]

24. Villalba L, Nguyen T, Feitosa RL Jr, Gunanayagam P, Anning N, Dwight K. Single-session catheter-directed lysis using adjunctive power-pulse spray with AngioJet for the treatment of acute massive and submassive pulmonary embolism. J Vasc Surg 2019; 70: 1920-6. [Crossref]

25. Li K, Cui M, Zhang K, Liang K, Liu H, Zhai S. Treatment of acute pulmonary embolism using rheolytic thrombectomy. EuroIntervention 2021; 17: e158-66. [Crossref]

26. Hsu MC, Weber CN, Mohammed MA, Gade TP, Hunt S, Nadolski GJ, et al. Thermal Changes during Rheolytic Mechanical Thrombectomy. J Vasc Interv Radiol 2016; 27: 909-12. [Crossref]

27. Dwarka D, Schwartz SA, Smyth SH, O’Brien MJ. Bradyarrhythmias during use of the AngioJet system. J Vasc Interv Radiol 2006; 17: 1693-5. [Crossref]

28. Dukkipati R, Yang EH, Adler S, Vintch J. Acute kidney injury caused by intravascular hemolysis after mechanical thrombectomy. Nat Clin Pract Nephrol 2009; 5: 112-6. [Crossref]

29. Qanadli SD, El Hajjam M, Vieillard-Baron A, Joseph T, Mesurolle B, Oliva VL, et al. New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. AJR Am J Roentgenol 2001; 176: 1415-20. [Crossref]

30. Schulman S, Agerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202-4. [Crossref]

31. Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al.; Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011; 21: 2527-41. [Crossref]